

Accepted Manuscript

Epigenetic Deregulation in Myeloid Malignancies

Kristen M. Meldi, Maria E. Figueroa

PII: S1931-5244(14)00142-X

DOI: [10.1016/j.trsl.2014.04.012](https://doi.org/10.1016/j.trsl.2014.04.012)

Reference: TRSL 779

To appear in: *Translational Research*

Received Date: 24 January 2014

Revised Date: 14 April 2014

Accepted Date: 17 April 2014

Please cite this article as: Meldi KM, Figueroa ME, Epigenetic Deregulation in Myeloid Malignancies, *Translational Research* (2014), doi: 10.1016/j.trsl.2014.04.012.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Epigenetic Deregulation in Myeloid Malignancies

Kristen M. Meldi¹ and Maria E. Figueroa¹

University of Michigan Medical School, Department of Pathology, Ann Arbor, MI

Key words: Epigenetics, AML, MDS, Myeloid malignancies, DNA methylation, Histone modifications

Word Count: 5,048

Corresponding author:

Maria E Figueroa, M.D.
Assistant professor,
Department of Pathology,
University of Michigan Medical School,
109 Zina Pitcher Pl, BSRB 2019,
Ann Arbor, MI 48109-2200
Phone: 734-763-1865

Running Title: Epigenetic de-regulation in myeloid malignancies

Abbreviations: alpha-ketoglutarate, α -KG; 2-hydroxyglutarate, 2-HG; 5-hydroxymethylcytosine, 5hmC; 5-methylcytosine, 5mC; acute myeloid leukemia, AML; additional sex combs-like 1, ASXL1; azacytidine, AZA; chronic myelomonocytic leukemia, CMML; decitabine, DAC; disruptor of telomeric silencing 1-like, DOT1L; DNA methyltransferase 1, DNMT1; DNA methyltransferase 3A, DNMT3A; DNA methyltransferase inhibitor, DNMTi; enhancer of zestes 2, EZH2; embryonic ectoderm, EED; fumarate dehydrogenase, FH; homeobox A9, HOXA9; histone deacetylase, HDAC; histone deacetylase inhibitor, HDACi; hematopoietic stem cell, HSC; hematopoietic stem/progenitor cell, HSPC; Jumonji, AT rich domain 2, JARID2; Jumonji C, JmjC; isocitrate dehydrogenase 1/2, IDH1/2; menin binding motif, MBM; mixed lineage leukemia, MLL; myelodysplastic syndrome, MDS; myeloproliferative neoplasm, MPN; myeloid ecotropic viral integration site 1, MEIS1; nucleophosmin, NPM1; polycomb repressive complex 2, PRC2; succinate dehydrogenase, SDH; suppressor of zestes 12, SUZ12; ten-eleven translocation, TET; ubiquitously transcribed tetratricopeptide repeat, X chromosome; UTX

Download English Version:

<https://daneshyari.com/en/article/6156129>

Download Persian Version:

<https://daneshyari.com/article/6156129>

[Daneshyari.com](https://daneshyari.com)